Multimodal Treatment in Locally Advanced Esophageal Adenocarcinoma — Two Interventions Better Than Three?
Mené sur 438 patients atteints d'un adénocarcinome résécable de l'oesophage (durée médiane de suivi : 55 mois), cet essai randomisé multicentrique de phase III compare l'efficacité, du point de vue de la survie globale, d'une chimiothérapie périopératoire avec FLOT (fluorouracile, leucovorine, oxaliplatine et docétaxel) et d'une chimioradiothérapie préopératoire (radiothérapie combinée à carboplatine et paclitaxel)
Esophageal cancer is a highly lethal disease and the seventh leading cause of cancer-related death. In 2022, there were 511,000 new cases of esophageal cancer and 445,000 deaths from esophageal cancer worldwide.1 Esophageal cancer is made up of two distinct cancers arising in the same organ, with different causative factors and different genomic characteristics. Whereas esophageal squamous-cell carcinomas are more prevalent worldwide (85% of new cases of esophageal cancer), adenocarcinomas of the esophagus and esophagogastric junction (hereafter referred to as esophageal adenocarcinomas) are predominant in developed countries, comprising 75% of the new cases of esophageal cancer in the United States . . .
New England Journal of Medicine , éditorial, 2024